1Vollebergh MA, Jonkers J, Linn SC. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomark- ers [J ]. Cell Mol Life Sci,2012,69(2):223-245.
2Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection[J]. Nat Rev Cancer, 2012,12(1):68-78.
3Foulkes WD. Inherited susceptibility to common cancers [J]. N Engl J Med,2008,359(20):2143-2153.
4Li WF, Hu Z, Rao NY, et al. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identi- fied[J]. Breast Cancer Res Treat, 2005,110(1):99-109.
5Zhang J, Pei R, Pang Z, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer[J]. Breast Cancer Res Treat, 2012,132(2): 421-428.
6Evans DG, Baildam AD, Anderson E, et al. Risk reducing mas- tectomy: outcomes in 10 European ceutres [J]. J Med Genet, 2009,46(4):254-258.
7Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality [J]. JAMA, 2010,304(9):967-975.
8Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contra- lateral breast cancer in BRCA1 and BRCA2 carriers: an update [ J ]. Int J Cancer, 2006,118(9):2281-2284.
9Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamox- ifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [J].JAMA, 2006, 295(23): 2727-2741.
10Tutt A, Robson M, C, arber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-con- cept trlal[J]. Lancet, 2010,376(9737):235-244.
10Schouten PC, Marine F, Aulmann S, et al. Breast cancer with BRCAI-like DNA copy number profile recur less often than expectec after high-dose alkylating chemotherapy[J].Clin Cancer Res, 2014. [ Epub ahead of print].
